Results from IMBRUVICA® RESONATE-2 Study Provide Up to Seven Years of Progression-Free and Overall Survival Data in First-Line Chronic Lymphocytic Leukemia Biotech Investing
Phase 2 Fight Trial Continues To Show Improved Overall Survival With Bemarituzumab Plus Chemotherapy In Patients With FGFR2b+ Gastric And Gastroesophageal Cancers Biotech Investing
Trodelvy® Demonstrates Superior Outcomes to Standard of Care in Second-Line Treatment of Metastatic Triple-Negative Breast Cancer in Phase 3 ASCENT Study Biotech Investing
Bristol Myers Squibb to Take Part in Goldman Sachs 42nd Annual Global Healthcare Conference Biotech Investing
3D Systems Corporation, Amdocs Limited, Champignon Brands, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm Psychedelics Investing
Bristol Myers Squibb Presents Data from CheckMate -648 Showing Opdivo plus Chemotherapy and Opdivo plus Yervoy Significantly Improved Overall Survival Compared to Chemotherapy in Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma Biotech Investing
Merck's KEYTRUDA® Given After Surgery Reduced the Risk of Disease Recurrence or Death by 32% Versus Placebo as Adjuvant Therapy in Patients With Renal Cell Carcinoma Pharmaceutical Investing
LYNPARZA® Reduced the Risk of Invasive Disease Recurrence or Death by 42% Versus Placebo in Adjuvant Treatment of Patients With Germline BRCA Mutations and High-Risk HER2-Negative Early Breast Cancer in Phase 3 OlympiA Trial Pharmaceutical Investing
SHRMF Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Champignon Brands Inc. Shareholders of Class Action and Lead Plaintiff Deadline: June 9, 2021 Psychedelics Investing
WEDNESDAY DEADLINE ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Champignon Brands Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Psychedelics Investing
